Health Care · Pharmaceutical Preparations · Nasdaq · CIK 849146 · FYE Jun 30 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $6.29Day −0.94%Mkt cap $79MP/E (FY) 8.4×1Y −49.2%Off 52W high −58.1%Vol (1Y) 78.9%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,294 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest11.6% of sh out |
| Days to cover8.0d |
| 13F net flow (QoQ)+3.61% |
| Top-10 13F concentration76.1% |
| Next report (est.)2026-08-05 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)8.4× |
| Sales (TTM)$195.3M |
| Earnings (TTM)$5.8M |
| ROE32.3% |
| Net margin4.3% |
| ROIC83.0% |
| EPS growth 3Y46.2% |
| Sales growth 3Y3.5% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+3.8% |
| 1Y−49.2% |
| 3Y+39.5% |
| 5Y−9.7% |
| 10Y−45.9% |
| Since incept. (ann.)−9.4% |
Total return through 2026-07-30 · series begins 2005-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)78.9% |
| Ann. volatility (3Y)75.8% |
| Sharpe (1Y)−0.48 |
| Sharpe (3Y)0.53 |
| Max drawdown (1Y)−71.7% |
| Max drawdown (3Y)−83.9% |
| Beta (3Y vs SPY)1.14 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| CAPITAL MANAGEMENT CORP /VA | 2.4M | $11M | 19.09% | +14.4% |
| RENAISSANCE TECHNOLOGIES LLC | 867,704 | $4M | 6.78% | −6.0% |
| BlackRock, Inc. | 769,698 | $3M | 6.02% | −0.3% |
| VANGUARD CAPITAL MANAGEMENT LLC | 429,422 | $2M | 3.36% | new |
| DIMENSIONAL FUND ADVISORS LP | 276,196 | $1M | 2.16% | −2.7% |
| GEODE CAPITAL MANAGEMENT, LLC | 261,192 | $1M | 2.04% | +6.7% |
| ENVESTNET ASSET MANAGEMENT INC | 219,162 | $946,780 | 1.71% | +23.2% |
| GOLDMAN SACHS GROUP INC | 185,114 | $799,692 | 1.45% | −7.5% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-06 | $0.11 | −57.7% | $43.7M | −25.2% |
| 2025-12-31 | 2026-02-04 | $0.02 | −89.5% | $48.9M | −27.8% |
| 2025-09-30 | 2025-11-04 | $0.17 | +21.4% | $47.6M | +0.7% |
| 2025-06-30 | 2025-09-04 | — | — | $55.1M | +12.6% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-05 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
